NASDAQ:FLXN - Flexion Therapeutics Stock Price, News, Headlines & Rumors

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

Flexion Therapeutics Inc (NASDAQ:FLXN) issued its quarterly earnings results on Tuesday, August, 7th. The specialty pharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.22) by $0.06. The specialty pharmaceutical company had revenue of $3.80 million for the quarter, compared to analysts' expectations of $3.96 million. View Flexion Therapeutics' Earnings History.

Flexion Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November, 5th 2018. View Earnings Estimates for Flexion Therapeutics.

9 Wall Street analysts have issued 12-month target prices for Flexion Therapeutics' shares. Their forecasts range from $36.00 to $570.00. On average, they anticipate Flexion Therapeutics' stock price to reach $98.8889 in the next year. This suggests a possible upside of 363.2% from the stock's current price. View Analyst Price Targets for Flexion Therapeutics.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Flexion Therapeutics.

Flexion Therapeutics saw a decline in short interest in the month of July. As of July 31st, there was short interest totalling 10,518,815 shares, a decline of 3.7% from the July 13th total of 10,922,687 shares. Based on an average daily volume of 387,639 shares, the short-interest ratio is presently 27.1 days. Approximately 33.3% of the shares of the stock are sold short. View Flexion Therapeutics' Current Options Chain.

Some companies that are related to Flexion Therapeutics include Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Array Biopharma (ARRY), Opko Health (OPK), Blueprint Medicines (BPMC), Heron Therapeutics (HRTX), Akcea Therapeutics (AKCA), Amicus Therapeutics (FOLD), Ironwood Pharmaceuticals (IRWD), The Medicines (MDCO), Ascendis Pharma A/S (ASND), Emergent Biosolutions (EBS), Mallinckrodt (MNK), Supernus Pharmaceuticals (SUPN) and Global Blood Therapeutics (GBT).

News headlines about FLXN stock have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Flexion Therapeutics earned a daily sentiment score of 0.14 on Accern's scale. They also assigned news articles about the specialty pharmaceutical company an impact score of 47.78 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View Recent Headlines for Flexion Therapeutics.

Flexion Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Gilder Gagnon Howe & Co. LLC (9.17%), BlackRock Inc. (7.52%), Miller Value Partners LLC (7.02%), Peregrine Capital Management LLC (1.77%), Wasatch Advisors Inc. (1.72%) and Ardsley Advisory Partners (1.57%). Company insiders that own Flexion Therapeutics stock include David Arkowitz, Frederick W Driscoll, Mark Stejbach, Michael D Clayman, Neil Bodick, Samuel D Colella and Yamo Deniz. View Institutional Ownership Trends for Flexion Therapeutics.

FLXN stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Raymond James & Associates, Miller Value Partners LLC, BB&T Securities LLC, Alps Advisors Inc., Alps Advisors Inc., California Public Employees Retirement System and Raymond James Financial Services Advisors Inc.. View Insider Buying and Selling for Flexion Therapeutics.

FLXN stock was bought by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Zweig DiMenna Associates LLC, BlackRock Inc., Clearline Capital LP, Castleark Management LLC, Ardsley Advisory Partners, Bank of America Corp DE and Gagnon Securities LLC. Company insiders that have bought Flexion Therapeutics stock in the last two years include David Arkowitz, Mark Stejbach, Michael D Clayman, Neil Bodick, Samuel D Colella and Yamo Deniz. View Insider Buying and Selling for Flexion Therapeutics.

Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of FLXN stock can currently be purchased for approximately $21.35.

Flexion Therapeutics has a market capitalization of $868.25 million and generates $350,000.00 in revenue each year. The specialty pharmaceutical company earns $-137,480,000.00 in net income (profit) each year or ($4.16) on an earnings per share basis. Flexion Therapeutics employs 251 workers across the globe.

Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]